Published in Br J Cancer on July 22, 2014
Old drug, new trick: repurposing metformin for gynecologic cancers? Gynecol Oncol (2014) 1.11
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer (2016) 1.06
Dissecting the Dual Role of AMPK in Cancer: From Experimental to Human Studies. Mol Cancer Res (2015) 0.97
Why does obesity promote cancer? Epidemiology, biology, and open questions. Ecancermedicalscience (2015) 0.83
Long-term impact of preeclampsia on maternal endometrial cancer risk. Br J Cancer (2016) 0.77
The Impact of Diabetes on Gynecologic Cancer: Current Status and Future Directions. Curr Obstet Gynecol Rep (2015) 0.75
Metformin Use Is Associated with Reduced Incidence and Improved Survival of Endometrial Cancer: A Meta-Analysis. Biomed Res Int (2017) 0.75
Prospective evaluation of abnormal glucose metabolism and insulin resistance in patients with atypical endometrial hyperplasia and endometrial cancer. Support Care Cancer (2016) 0.75
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet (2008) 20.62
Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials (1998) 20.39
Metformin and reduced risk of cancer in diabetic patients. BMJ (2005) 13.04
The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (2005) 12.35
The Women's Health Initiative recruitment methods and results. Ann Epidemiol (2003) 8.42
The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol (2003) 7.49
Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res (2007) 7.42
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res (2006) 6.99
Insulin-like growth factors and neoplasia. Nat Rev Cancer (2004) 6.29
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene (2008) 5.85
Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev (2002) 5.34
Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med (1975) 5.33
Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) (2010) 4.36
Association of exogenous estrogen and endometrial carcinoma. N Engl J Med (1975) 3.89
Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev (2009) 3.53
Validity of diabetes self-reports in the Women's Health Initiative: comparison with medication inventories and fasting glucose measurements. Clin Trials (2008) 3.24
The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer (1988) 3.07
The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol (2003) 3.03
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One (2012) 2.84
Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med (1995) 2.83
The Women's Health Initiative Dietary Modification trial: overview and baseline characteristics of participants. Ann Epidemiol (2003) 2.64
Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia (2007) 2.54
Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol (2009) 2.42
The Women's Health Initiative calcium-vitamin D trial: overview and baseline characteristics of participants. Ann Epidemiol (2003) 2.42
Diabetes mellitus and breast cancer. Lancet Oncol (2005) 2.34
Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol (1995) 2.30
A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev (2008) 2.01
Epidemiology of endometrial cancer. Best Pract Res Clin Obstet Gynaecol (2001) 1.90
Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer (2010) 1.78
Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy. Gynecol Oncol (2009) 1.78
Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev (2010) 1.75
LKB1 and AMPK in cell polarity and division. Trends Cell Biol (2008) 1.72
Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression. Int J Gynecol Cancer (2011) 1.56
Lifestyle and endometrial cancer risk: a cohort study from the Swedish Twin Registry. Int J Cancer (1999) 1.44
Diabetes and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev (2007) 1.37
Diabetes and endometrial cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev (2001) 1.24
The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. Diabetes Obes Metab (2014) 1.23
Self-reported diabetes is a valid outcome in pragmatic clinical trials and observational studies. J Clin Epidemiol (2012) 1.21
Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol (2010) 1.11
Diabetes and endometrial cancer: an evaluation of the modifying effects of other known risk factors. Am J Epidemiol (2007) 1.10
Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells. J Clin Endocrinol Metab (2010) 1.09
Diabetes and endometrial cancer: effect modification by body weight, physical activity and hypertension. Br J Cancer (2007) 0.98
Insulin resistance: a significant risk factor of endometrial cancer. Gynecol Oncol (2012) 0.94
The role of preexisting diabetes mellitus on incidence and mortality of endometrial cancer: a meta-analysis of prospective cohort studies. Int J Gynecol Cancer (2013) 0.93
Metformin and the risk of endometrial cancer: a case-control analysis. Gynecol Oncol (2013) 0.82
Pre-existing diabetes and breast cancer prognosis among elderly women. Br J Cancer (2015) 0.85
Comparing US paediatric and adult weight classification at the transition from late teenage to young adulthood. Pediatr Obes (2015) 0.75